ZENAS BIOPHARMA INC
ZBIONASDAQTrading Snapshot
- Day Range
- $28.37 – $29.57
- 52-Week Range
- $13.50 – $44.60
- Volume (shares)
- 373,024
- Avg Volume (shares)
- —
- Shares Outstanding
- 65.2M
- Next Earnings
- 2026-11-18
Fundamentals Snapshot
- Annual Revenue
- $10M
- Last Q Revenue
- $1M
- P/E Ratio
- —
- P/S Ratio
- 1870.4x
- EPS (TTM)
- $-8.97
- Dividend Yield
- —
- Dilution (1yr)
- +11.3%
ZENAS BIOPHARMA INC
ZBIO
StockOtter · stockotter.spaceAbout ZENAS BIOPHARMA INC
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Zenas BioPharma, Inc. (ZBIO) R&D Event: Obexelimab in SLE and ZB021 Development Transcript
Zenas BioPharma, Inc. (ZBIO) R&D Event: Obexelimab in SLE and ZB021 Development Transcript
Wall Street Analysts Predict a 77.61% Upside in Zenas BioPharma, Inc. (ZBIO): Here's What You Should Know
The mean of analysts' price targets for Zenas BioPharma, Inc. (ZBIO) points to a 77.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in ra
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and comm
Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026
WALTHAM, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients living with autoimmune
Zenas BioPharma to Host Virtual R&D Event
WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and comm
Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve
Zenas BioPharma (ZBIO) is advancing obexelimab for IgG4-RD, with FDA acceptance and a May 2027 PDUFA date, positioning as a long-term maintenance therapy. ZBIO maintains a sizable cash runway, with pro forma balances cov